Medical Oncology

, 26:437

Translational research in complex etiopathogenesis and therapy of hematological malignancies: the specific role of tyrosine kinases signaling and inhibition

  • Karmen Stankov
  • Sunčica Stankov
  • Stevan Popović
Original Paper

DOI: 10.1007/s12032-008-9143-2

Cite this article as:
Stankov, K., Stankov, S. & Popović, S. Med Oncol (2009) 26: 437. doi:10.1007/s12032-008-9143-2

Abstract

During the recent genomics and proteomics era, high-resolution, genome-wide approaches have revealed numerous promising new drug targets and disease biomarkers, accelerating and emphasizing the need for targeted molecular therapy compounds. Significant progress has been made in understanding the pathogenesis of hematological malignancies there by, revealing new drug targets. Introduction of multiple new technologies in cancer research have significantly improved the drug discovery process, leading to key success in targeted cancer therapeutics, including tyrosine kinase inhibitors. The studies of receptor tyrosine kinases and their role in malignant transformation are already translated from the preclinical level (cell-based and animal models) to clinical studies, enabling the more complete understanding of tumor cell biology and improvement of tumor therapy.

Keywords

LeukemiaReceptor protein–tyrosine kinasesProtein kinase inhibitors

Copyright information

© Humana Press Inc. 2008

Authors and Affiliations

  • Karmen Stankov
    • 1
    • 2
  • Sunčica Stankov
    • 3
  • Stevan Popović
    • 4
  1. 1.Department of Biochemistry, Medical facultyUniversity of Novi SadNovi SadSerbia
  2. 2.CEA/Institut de Génomique Centre National de GénotypageEvry CedexFrance
  3. 3.Health Center Novi SadNovi SadSerbia
  4. 4.Hematology Clinics, Medical facultyUniversity of Novi SadNovi SadSerbia